Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 6/20 | 0.58 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.44 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3455551 | 0.79 | AURKA (0.67) | AURKAAURKBDAO | |
| SCHEMBL6524053 | 0.76 | AURKA (0.58) | AURKAAURKBDAOKDM4E | |
| SCHEMBL6518381 | 0.76 | AURKA (0.58) | AURKAAURKBDAOKDM4E | |
| SCHEMBL679019 | 0.74 | AURKA (1.00) | AURKAAURKBDAO | |
| SCHEMBL23293688 | 0.73 | PSMD14 (0.56) | NR4A2MAP2K1PSMD14KDM4E | |
| SCHEMBL17818802 | 0.71 | NR4A2 (0.58) | AURKBNR4A2MAP2K1PKN2CREBBP | |
| SCHEMBL6007667 | 0.70 | NR4A2 (0.53) | NR4A2PKN1PKN2CREBBPKDM4E | |
| SCHEMBL6527216 | 0.70 | AURKA (0.61) | AURKAAURKBDAOKDM4E | |
| SCHEMBL2015365 | 0.70 | GABRA1 (0.57) | AURKAAURKBKDM4E | |
| SCHEMBL17249871 | 0.70 | NR4A2 (0.53) | NR4A2CREBBPKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735584-B2 | Protein kinase inhibitors and use thereof | MERCK PATENT GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| EP-2254889-B1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK PATENT GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-2254889-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | Merck Patent GmbH (DE) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009108670-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MERCK SERONO S.A. (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053906-A1 | PROTEIN KINASE INHIBITORS AND USE THEREOF | MAP4K2, MAP3K20, MAP4K1 | AURKA 538/4885AURKB 487/4885NR4A2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.